Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis
Authors:
- Sébastien ConusSCSébastien Conus
- Alex StraumannASAlex Straumann
- Eva BettlerEBEva Bettler
- Hans-Uwe SimonHans-Uwe Simon
- 1 July 2010
- journal article
- other
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 126 (1) , 175-177
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trialGut, 2009
- Regulatory Lymphocytes and Intestinal InflammationAnnual Review of Immunology, 2009
- Differential expression of the interleukin 5 receptor α isoforms in blood and tissue eosinophils of nasal polyp patientsAllergy, 2009
- Anti–IL-5 (mepolizumab) therapy does not alter IL-5 receptor α levels in patients with eosinophilic esophagitisJournal of Allergy and Clinical Immunology, 2009
- Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defenseNature Medicine, 2008
- Cytokine Expression in Healthy and Inflamed Mucosa: Probing the Role of Eosinophils in the Digestive TractInflammatory Bowel Diseases, 2005
- Review : Role of mast cells in gastrointestinal mucosal defenseBIOCELL, 2003
- IL-5 Promotes Eosinophil Trafficking to the EsophagusThe Journal of Immunology, 2002
- Eosinophil infiltration and degranulation in normal human tissueThe Anatomical Record, 1998